Kornimate/medical-research-clean huggingface dataset:
development of personalized balanced nutrition concept through an it platform

Conditions: Child Allergy; Allergic Reaction

Summary: by achieving effective cooperation between the children's hospital srebrnjak (chs), the reference center for clinical allergology in children of the ministry of health, and in2 ltd., part of constellation software inc., it is planned to develop an it platform for the introduction of personalized balanced nutrition in kindergartens. the collected data which include the screening of the population, anthropometrical measurements, physical activity status, and medical examination, will be used to create a registry of allergies. through the implementation of research activities, it is expected to develop an it platform for personalized balanced nutrition of preschool children, which consists of a developed information system for continuous monitoring using a website and/or a mobile application.

this study will involve kindergarten children (aged 1-6 years). the research takes place in six different phases: 1) development of the information system and data integration, 2) classification of target groups of kindergarten children according to nutritional status, 3) anthropometric monitoring of the development of kindergarten children, 4) establishment of an electronic register of allergies, 5) implementation of an information platform in kindergartens, and 6) assessment of the validity of platform. the research will include a minimum of 450 participants from split, osijek and zagreb county. based on the completed standardized questionnaires the target groups of kindergarten children will be classified according to their nutritional status: 1. children who have a developed food allergy 2. children at risk of developing mild, moderate or severe allergic reaction to food 3. children with an allergological indication the children with allergological indication (c) will be sent for further specialist evaluation, diagonstics and nutritionist advice at chs. the investigators will monitor how many kindergarten children have developed food allergy, food intolerance and another allergy (eg. inhalation allergy). children with another type of allergy will be the refference control.

Eligibility criteria:
inclusion criteria: * parental approval * children from 1 to 6 years old exclusion criteria: * chromosomal abberations * neurological disorders that affect oral motorics * chronic gastrointestinal disorders * severe metabolic disorders

Keywords: allergy perosnalized nutrition obesity
the physiological effects of electromagnetic emissions on the general condition of the patient

Conditions: Electromagnetic Emissions and Emotional Disorder; Electromagnetic Emissions and Medication Savings

Summary: hospital patients usually experience anxiety caused by physiological, psychological and environmental stimuli. this emotional state corresponds to the psychophysiological response to a perceived threat. the investigator's goal is to use a non-drug approach to these problems which would help improve the quality of life of patients, prevent the consumption of anti-anxiety drugs / antidepressants; and thus to reduce the direct cost in terms of treatment, but also to reduce the indirect costs linked to work stoppages and the consumption of the care offer. working hypothesis: local magnetic muscle stimulation improves people's well-being and relaxation

primary objective : describe the effect of the intervention on the level of anxiety / depression in patients with anxious and / or depressive characteristics secondary objectives: * describe the variation in the quality of life of patients before and after the intervention * describe the variation in drug consumption * describe the use of post intervention hospitalization * describe the variation in the quality of sleep before and after the intervention * describe the timeframe for returning patients to professional activity

Eligibility criteria:
inclusion criteria: * major patient hospitalized for the management of a chronic pathology and / or its complications; * patient with a hospital anxiety and depression scale score (had) ≥ 8 for items assessing anxiety disorders; and a had score ≥ 8 for the items assessing depressive disorders. * subject affiliated to a social security scheme or beneficiary of such a scheme * no participation in another clinical study exclusion criteria: * minor patient * pregnant and breastfeeding women * had score \<8 for items evaluating anxiety disorders or a had score \<8 for items evaluating depressive disorders * major subject protected by law, under curatorship or tutorship

Keywords: anxiety depression quality of life medication savings electromagnetic emissions
the preemptive analgetic potency of low dose s-ketamine

Conditions: Pain

Summary: the primary hypothesis is improved postoperative analgetic quality using s-ketamine, particularly in patients suffering from chronic pain.

the investigators are dealing mainly with the finding of the right dosage for the optimal safety and efficacy of s-ketamine, but also discovering new possible areas of investigation (e.g. anti-depressive effect, anti-neuropathic effect).

Eligibility criteria:
inclusion criteria: * scheduled for major abdominal surgery * suitable for pca * cardio-vascular stable * age: 18+ * between 50-120kg bw * asa 1-3 * good compliance for pain monitoring exclusion criteria: * allergy to s-ketamine * severe liver or kidney dysfunction * severe coronary disease * pregnancy * present or past psychotic disorders * addiction to alcohol or opioids * poor compliance
long term follow-up study for individuals with hemoglobin disorders after hematopoietic cell transplant or gene therapy

Conditions: Hemoglobin Disorder

Summary: this is a prospective, longitudinal, non-therapeutic study which includes routine assessment for long-term effects, as per fda guidelines after receipt of an allogeneic hct or autologous genetically modified cellular products for hemoglobin disorders. primary objective: - to provide long term follow up, for individuals with hemoglobin disorders undergoing allogeneic hematopoietic stem cell transplantation (hct) or receipt of an autologous genetically modified cellular product to treat their hemoglobinopathy. for individuals receiving a genetically modified cellular product, this long term follow up study is in accordance with the guidelines provided by the food and drug administration (fda).

this protocol will provide a mechanism to appropriately monitor individuals with hemoglobin disorders that have received an allogenic hct or an autologous genetically modified cellular product for hemoglobinopathies. monitoring will include potential long-term adverse effects after receipt of these treatments, as well as long-term monitoring after the receipt of the genetically modified cellular product.

Eligibility criteria:
inclusion criteria: * receipt, or planned receipt, of an allogeneic hsct or infusion of genetically modified autologous cells for hemoglobin disorders within 15 years prior to enrollment exclusion criteria: * inability or unwillingness of research participant and/or legal guardian/ representative to provide written informed consent.

Keywords: transplant gene therapy
acceptance and commitment therapy for chronic pain in cancer survivors

Conditions: Chronic Pain

Summary: a study to help manage chronic pain in cancer survivors through acceptance and commitment therapy (act) after undergoing active cancer treatment, such as surgery, chemotherapy, and/or radiation.

this study attempts to apply effective pain management interventions from other chronic pain populations to those of cancer related populations. it will assess the ability of act to alleviate chronic cancer related pain and evaluate ease of implementation of treatment. patients will be allocated to either the intervention group (act) or the control group, getting them the usual course of treatment.

Eligibility criteria:
inclusion criteria: 1. provision to sign and date the consent form 2. stated willingness to comply with all study procedures and be available for the duration of the study 3. be a male or female aged 18-100 4. have pathology confirmed diagnosis of a solid tumor cancer 5. be three or more months out from active cancer treatment (surgery, chemotherapy, and/or radiation) 6. endorses experiencing pain for three or more months prior to eligibility screening 7. indicates moderate to severe difficulties with pain interference as related to their cancer experience, with a score of 4 or higher on the pain interference item from the chronic pain grading questionnaire 8. shows no evidence of cancer disease (ned) or with stable, chronic disease under "watchful waiting" 9. fluent in english 10. psychiatric stability as assessed by chart review and study personnel (e.g., not exhibiting symptoms consistent with diagnoses of serious mental illness such as active psychosis or mania) exclusion criteria: 1. having pain that can be solely attributed to a diagnosis outside of their cancer experience 2. presenting with barriers to group participation (e.g., social anxiety) or when group-based provision of care would impede participant's treatment or that of other group members 3. patients with a diagnosis of malignant neoplasm of the brain (icd-10 c71) or malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system (icd-10 c72).

Keywords: acceptance and commitment therapy cancer survivor group based pain management
effect of combination of morphine+fentanyl on emergence delirium in patients of cleft lip and palate repair

Conditions: Anesthesia Emergence Delirium

Summary: emergence delirium and recovery profile in patients undergoing cleft lip and cleft palate repair with either combination of morphine plus fentanyl or fentanyl alone


Eligibility criteria:
inclusion criteria: * asa 1 patients undergoing cleft lip and palate repair exclusion criteria: * cns disorders * respiratory infection * gerd
research on the effect and mechanism of aerobic exercise on pd

Conditions: Parkinson's Disease; Physical Exercise

Summary: this trial is expected to recruit patients with primary parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on parkinson's disease and explore its mechanism

this trial is expected to recruit patients with primary parkinson's disease who are distributed into tremor group and stiff group and give them the same kind of four consecutive weeks of aerobic exercise to observe its effect on parkinson's disease and explore its mechanism

Eligibility criteria:
inclusion criteria: * participants were diagnosed primary pd according to the 2015 mds diagnostic criteria * participants are between 55 and 65 years old exclusion criteria: * severe heart * liver dysfunction * kidney dysfunction * severe cognitive dysfunction * severe anxiety and depression * history of mental illness * history of cerebral infarction or ischemic attack in the past three months * acute myocardial infarction or acute coronary in the past three months * parkinson's pulse syndrome * medication history (drugs that improve blood circulation in the brain and increase the excitability of the nervous system)

Keywords: parkinson's disease physical exercise mechanism
a registered cohort study on color discrimination deficit associated with neurodegenerative disorders.

Conditions: Neurodegenerative Disorders

Summary: color discrimination deficit is a common manifestation of alzheimer's disease (ad). however, the pathophysiology of this dysfunction remains poorly understood. the aim of the present study was to evaluate color discrimination using the farnsworth-munsell 100 hue test in patients with ad and mild cognitive impairment (mci), compared with age-matched control subjects. as a secondary aim, we evaluated whether the outcomes of these visual tests were associated with cognitive.


Eligibility criteria:
inclusion criteria: * all patients underwent extensive clinical examination including thorough neurological and somatic examination by a specialized neurologist or geriatrician and extensive neuropsychological examination by a trained psychologist. ad was diagnosed according to the nincds-adrda criteria. exclusion criteria: * we excluded individuals with noncompensated somatic illnesses, a history of a psychiatric disorder, color blindness, ophthalmological pathology, severe cranial trauma, focal neurological signs or magnetic resonance imaging examinations suggestive of cerebrovascular disturbances.
a study evaluating the safety and activity of pegylated recombinant human arginase (bct-100)

Conditions: Cancer; Pediatric Solid Tumor; Pediatric AML; Pediatric ALL

Summary: parc is an international phase i/ii trial evaluating the safety and activity of pegylated recombinant human arginase (bct-100) in children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). currently the outcomes for these patients are poor and the therapeutic options are limited with a significant toxicity burden. therefore new treatments which work in different ways to standard chemotherapy are urgently needed. research has shown that arginine (a nutrient) is important in the survival of cancer cells. bct-100 is a drug which can deplete arginine levels and starve cancer cells - a completely new approach. bct-100 has been tested in adults and shown to be active with almost no side-effects. this trial will test whether this dose of bct-100 is also safe and active in children with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma. the trial will also study how bct-100 is broken down in the body and look for new biological markers of treatment response. up to 64 children with relapsed cancers will be recruited over 2 years.


Eligibility criteria:
inclusion criteria: * aged 1- \<25 years old at the time of study registration * histologically confirmed disease in one of the following four groups: * group 1 - acute lymphoblastic leukaemia (all) and acute myeloid leukaemia (aml) * group 2 - neuroblastoma group 3 - sarcoma * group 4 - high grade glioma (as defined by 2016 who cns classification) * radiological or laboratory evidence of disease progression (during or after completion of first line treatment) or any subsequent recurrence (biopsy at relapse is not mandated). * measurable bone marrow disease (group 1) or at least one evaluable radiological site of disease (group 2, 3 and 4). * adequate liver function defined as a total bilirubin ≤1.5x the upper limit of normal for age and alt ≤ 3x the upper limit of normal for age * documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry * sexually active patients must agree to use adequate and appropriate contraception while on study drug and for 12 months following treatment discontinuation * written informed consent given by patient and/or parents/legal representative exclusion criteria: * previous treatment with another therapeutic arginine depleting drug (bacterial or human) or arginase inhibitor * presence of any ≥ ctcae grade 3 clinically significant treatment-related toxicity from prior therapies * pregnant or lactating female * evidence of uncontrolled infection

Keywords: arginine arginase children young adult
a study to learn about study medicine called pf-07261271 in healthy people

Conditions: Healthy

Summary: the purpose of this clinical trial is to learn about the safety and effects of the study medicine pf-07261271 for the potential treatment of inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * healthy individuals as determined by medical evaluation * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). exclusion criteria: * clinically significant medical conditions * history of hiv infection, hepatitis b, or hepatitis c * bp ≥140 mm hg (systolic) or ≥90 mm hg (diastolic) * clinically relevant ecg abnormalities * previous study drug administration within 30 days or 5 half-lives of first planned dose * history of drug/alcohol abuse or \>20 cigarettes/day

Keywords: healthy volunteer healthy ibd inflammatory bowel disease
the lived experiences of persons with early stage non-small cell lung cancer and their significant other(s) following surgery: a rapid ethnographic approach

Conditions: Lung Cancer

Summary: to understand the lived experiences, thoughts and habits about exercise and pa of persons with early stage non-small cell lung cancer and their significant other(s) following surgery.

it is important to gather information on the lived lives of persons and their significant other(s) following surgery for early stage non-small cell lung cancer (nsclc). the adaptations these persons make, the challenges they face and their personal experiences need to be investigated so their thoughts and habits about exercise and physical activity (pa) can be better understood. in this way, rehabilitation programs focused on exercise and pa can be better individualized. the individualization of such programs is heavily influenced by the person's experiences, including beliefs and expectations regarding exercise and pa. observations of and informal conversations with persons with early stage nsclc and their significant other(s) following surgery will offer insight into the challenges faced by these individuals and the opportunities for exercise and pa, how this does and could fit, within their everyday lives so this can be enhanced. it is important to align exercise and pa to everyday activities, to make it meaningful to individuals (more likely to engage) and to obtain sustained effects in the long term. the investigators expect this study to show the highly personal views and behaviour of these persons, warranting an equally personal communication approach to discuss these issues with these persons in light of developing individualized rehabilitation programs.

Eligibility criteria:
inclusion criteria: * persons who got surgery for early stage i-iiia nsclc, one to three months before inclusion; * if persons received adjuvant chemotherapy/radiotherapy, the inclusion window is one to three months after the end of adjuvant chemotherapy/radiotherapy. if persons receive adjuvant immunotherapy after the end of adjuvant chemotherapy, persons can be included during the immunotherapy; * adults (18+ year); * ability to give informed consent. exclusion criteria: * persons having progressive or recurrent lung cancer; * persons who had other malignancies in the last 2 years; * persons who do systematically perform or plan to perform structured exercise; * persons not living independently at home (e.g. care home, psychiatric institution); * psychiatric or cognitive disorders; * not understanding and speaking dutch; * not living at home (e.g. nursing home, prison ...).
the paco study ("personnalité alzheimer comportement")

Conditions: Alzheimer Disease

Summary: alzheimer's disease is characterised by a loss of cognitive functions and behavioural problems as set out under the term "behavioural and psychological symptoms of dementia (bpsd)". the impact of bpsd in everyday life has heavy consequences for the patient and their family. the precocity of incidence, the frequency and the intensity of the bpsd are associated with a rapid decline in cognitive functions, an alteration in the activities of daily living, and a decrease in the quality of life for both the patient and the helper, an increased risk of hospitalisation and of institutionalisation as well as an increase in the cost to the health system. a greater understanding of the risk factors for the occurence of the bpsd would better allow the detection of patients who are particularly at risk for bpsd, to anticipate the crisis situations by proposing early and adapted care, and to better target the medicinal therapies. certain observational arguments or results of retrospective studies speak in favour of the role of the basic personality in the occurence of bpsd in alzheimer's disease. the investigators propose to clarify this role through a prospective study.


Eligibility criteria:
inclusion criteria: * male or female subject aged over 50 years ; * in-patient or out-patient at one of the centres participating in the study ; * meeting all the diagnostic criteria for dementia due to ad (nincds adrda, cdr 1 or 2) or pre-dementia with a cdr of 0.5 (berr et al., 2006, dubois et al, 2007) ; * covered by the state's social security system ; * with sufficient visual, auditory and oral and written french language skills to complete the clinical and neuropsychological evaluations ; * accompanied by a caregiver in sufficient contact with the subject to be able to assess their personality and note the onset of changes in behaviour. exclusion criteria: * patients with a progressive and/or poorly managed psychiatric pathology (patients with stabilised depression could be included in the study) ; * patients taking any neuroleptic psychotropic medication ; * patients taking other psychotropic medication, with the exception of any antidepressant, hypnotic, anxiolytic, acetylcholinesterase inhibitors or memantine which has been prescribed and stabilised for more than 3 months * patients with forms of dementia with an aetiology other than that of alzheimer's disease (frontotemporal dementia, vascular dementia, lewy body dementia, and types of dementia that arise as a result of an underlying untreated disease, such as dysthyroidism, vitamin b12 or folic acid deficiency, syphilis, anaemia or hydroelectrolytic disorders) ; * patients with serious, progressive or unstable pathologies which could interfere with the variables under consideration ; * deafness or blindness which could compromise evaluation of the patient ; * pregnancy ; * patients under any type of guardianship or belonging to a restricted category as laid out in the public health code ; * patients without a suitable caregiver willing to participate.

Keywords: psychiatry behaviour alzheimer's personality
objective and subjective evaluation of ophthalmic lenses with extra power

Conditions: Asthenopia

Summary: to evaluate subjective visual performance and objective visual parameters when wearing ophthalmic lenses with extra power (+0.4 d or +0.6 d), and ophthalmic lenses with a selective blue cut filter.


Eligibility criteria:
inclusion criteria: * subjective report of visual fatigue * non-presbyopes * permanent wearers who wear glasses for at least 5 hours a day * distance refractive error within the range of \[+6.00 to -6.00\]\* (with cylinder in the negative form), * cylindrical component of the refractive error within the range of 0 to 2 d in both eyes, * anisometropia ≤ 1.00 d in sperical equivalent, * visual acuity of +0.10 logmar or better in each eye with new prescription at distance (high contrast/high luminance), * distance visual acuity difference ≤0.20 logmar between right and left eye (high contrast, high luminance) * near binocular visual acuity of +0.10 logmar or better with a new prescription (high contrast, high luminance), * study frame characteristics: frame b size at least 22 mm exclusion criteria: * vulnerability of the subject, * participation in another study which might have an influence on vision or interfere with study assessments, * binocular vision problems, * known ocular pathology (e.g., age-related macular degeneration, glaucoma...), * any previous ocular surgery which might have an influence on vision or interfere with study assessments (e.g., iridectomy, refractive surgery...), * any untreated and/or uncontrolled systemic condition which might have an influence on vision, or interfere with study assessments (e.g., uncontrolled diabetes, uncontrolled high blood pressure...), * any medical treatment or medication that might have an influence on vision or interfere with study assessments (e.g., antidepressants, drugs with atropinic effects...), * knowledge/expertise in optometry, ophthalmic lenses, or optics based on past or current professional activity (e.g., optometrists, opticians, ophthalmologists...)